HTDK Deepens Nationwide Strategic Channel Partnership with Aohua Endoscopy to Accelerate the Adoption of Innovative Domestic High-End Endoscopy Solutions

HTDK has officially entered a nationwide strategic channel partnership with Shanghai Aohua Endoscopy Co., Ltd. (SSE: 688212). The collaboration initially focuses on the gastrointestinal endoscopy product portfolio, with regional cooperation already underway in South China and other key markets, while market expansion for the ENT and respiratory product lines is being advanced in parallel. Leveraging the complementary strengths of both companies in product innovation, channel resources, and medical device commercialization services, the partnership aims to deepen channel collaboration and strengthen market operations, further accelerating the market expansion of innovative domestic high-end endoscopy solutions.

Since the launch of the partnership, both parties have actively promoted business development across key regional markets. As of the second quarter of 2026, the collaboration has generated cumulative sales exceeding RMB 20 million, marking a significant milestone and establishing a solid foundation for further strategic cooperation.

As the first listed flexible endoscopy company in China, Shanghai Aohua Endoscopy has specialized in the research, development, and manufacturing of medical endoscopy products for more than two decades and has become an important innovator in China’s domestic high-end endoscopy sector. The company has established a comprehensive product portfolio covering gastrointestinal endoscopy, respiratory endoscopy, ENT endoscopy, and surgical endoscopy, and continues to advance endoscopic diagnosis and treatment technologies through independent innovation. In recent years, Aohua’s products have been adopted by numerous medical institutions in China and overseas, supporting high-quality minimally invasive clinical solutions.

Under the partnership, HTDK will leverage its nationwide medical device commercialization platform and channel operation capabilities to provide Aohua with market expansion, channel collaboration, and downstream operational support. The cooperation is expected to further strengthen development in key regional markets, enhance product accessibility, and improve commercialization efficiency. Both companies will continue to deepen cooperation across Aohua Endoscopy product portfolio and expand coverage in strategically important healthcare markets nationwide.

Aohua’s portfolio includes electronic gastrointestinal endoscopes, AI-assisted endoscopic diagnostic platforms, single-use sterile endoscopes, and related diagnostic and therapeutic consumables. These solutions are widely used in applications such as early gastrointestinal cancer screening, respiratory disease diagnosis, ENT treatment, and minimally invasive surgical procedures. Supported by technologies including 4K high-definition optical imaging, A-FICE spectral chromoendoscopy, and real-time AI lesion detection, Aohua continues to drive the development of precision and intelligent endoscopic diagnosis and treatment.

“Domestic high-end medical devices are entering a significant period of growth and opportunity. Aohua remains committed to independent innovation and continuous technological advancement in endoscopy, providing clinicians with high-quality and competitive solutions. By deepening the nationwide strategic channel partnership with HTDK, we will further integrate the strengths of both organizations, accelerate market expansion and commercialization, and bring innovative endoscopy solutions to more healthcare institutions,” said the CEO of Aohua Endoscopy.

“This partnership further expands HTDK’s commercialization footprint in the field of minimally invasive diagnosis and treatment,” said the CEO of HTDK. “Going forward, HTDK will continue to leverage its medical device commercialization platform to deepen collaboration with Aohua and support broader market access and greater commercial value realization for innovative domestic medical technologies.”

Looking forward, both companies will continue to expand the scope of cooperation across additional regions and product lines, explore new commercialization models for domestic high-end medical devices, and jointly contribute to the innovation and development of China’s healthcare industry.